Company profile
Apellis Pharmaceuticals, Inc.
Pipeline6 assets
- APL-3007 + SYFOVREAPL-3007 / SYFOVRE / C3 / siRNA + pegcetacoplan injection / OphthalmologyGeographic atrophyPhase 2
- EMPAVELIpegcetacoplan / EMPAVELI / C3 / C3 inhibitor / Rare diseaseFSGSPivotal Phase 2/3DGFPivotal Phase 3
- RNA therapiesRNA therapy / NeurologyUndisclosedPreclinical
- APL-9099: Gene-edited FcRn therapyAPL-9099 / FcRn / gene-edited therapy / Multiple therapeutic areasUndisclosedPreclinical
- Gene-edited complement therapiescomplement / gene-edited therapy / Multiple therapeutic areasUndisclosedPreclinical
- Oral complement inhibitorcomplement / oral complement inhibitor / Multiple therapeutic areasUndisclosedPreclinical
Latest news0 items
All newsNo recent headlines yet.
New company coverage will appear here as soon as it is picked up.